Cranswick PLC (CWK) — Investment Research Note

Executive summary

Cranswick is a vertically integrated UK food producer (fresh pork, poultry, convenience, gourmet, pet food) supplying the UK grocery multiples, with 23 production sites, ~16,000 employees and an increasingly self-sufficient pig farming and feed milling operation. Across the period covered, the business delivered consistent volume-led revenue growth (FY24 £2,599m → FY25 £2,723m, H1 FY26 +10.4% YoY), modest margin expansion (adj. operating margin 6.1% H1 FY23 → 7.7% H1 FY26) and £600m+ of capex into scaled, automated facilities, while making accretive bolt-on acquisitions (Atlantica, Ramona's, Froch, Elsham Linc, Piggy Green/Fornham, JSR Genetics, Blakemans, Fridaythorpe). The single most important point for valuation today is that the shares already capitalise the high quality and growth trajectory — the multiple leaves little margin of safety, and none of this growth is AI-driven.

Fair value estimate

Methodology: Forward earnings multiple, cross-checked vs. UK consumer staples peers. DCF/sum-of-parts are not informative given the modest margin/uniform mix.

Key assumptions:

• FY26 (52 weeks to 28 March 2026) adjusted PBT guidance: market expectations £211.3m–£216.0m, mean £213.4m, with management guiding "upper end" 2026-01 Q3 trading update.
• Tax rate ~26.5% 2025-11 H1 FY26.
• Weighted avg shares ~53.5m → FY26 adj. EPS estimate ~290–297p.
• Applied multiple range 15–18x forward adj. EPS (sector range for UK food producers with mid-single-digit growth and ~18% ROCE).

Fair value range: 4,400p – 5,300p per share (mid ~4,850p / £48.50). Implied market cap range: £2,355m – £2,836m (mid ~£2,595m).

vs. current market cap £2,926.5m → mid-case downside of ~11%; upper-bound roughly fair, lower bound implies ~20% downside.

View: fair-to-slightly overvalued.

Sector context

Sector classification confirmed: Consumer Staples / Food, Beverage & Tobacco. Cranswick's quality is above typical sector peers — ROCE of 18.2% (H1 FY26), net debt/EBITDA <0.5x, consistent dividend growth, integrated farm-to-fork model. Listed UK peers: Hilton Food Group (HFG), Greencore (GNC), and to a lesser extent Premier Foods (PFD). Cranswick trades at a meaningful premium to all three, justified by its margin trajectory and ROCE, but limiting upside.

Investment thesis (3 bullets)

1. Volume-led growth supported by record capex programme. H1 FY26 revenue +10.4% with 6.6% volume growth and ongoing capacity additions (£100m Hull pork expansion, £25m Worsley houmous, £14m Lincoln pet) — capacity coming online supports growth beyond FY26 2025-11 H1 FY26 results.
2. Self-sufficiency strategy reduces input volatility. Pig self-sufficiency now ~55%, feed milling self-sufficiency on path to 40%+ post-Fridaythorpe, JSR Genetics owned — gives margin resilience versus pure processors 2025-11 H1 FY26 results.
3. Fortress balance sheet and consistent cash generation. Net debt £127.3m vs. adj. EBITDA run-rate ~£325m (≈0.4x), free cash conversion 89.9% 2025-11 H1 FY26 results, with new £360m unsecured RCF to July 2029 — supports continued bolt-on M&A and capex without dilution risk.

Key risks (3 bullets)

1. Customer concentration. Three customers = 24% + 15% + 11% = 50% of revenue 2025-11 H1 FY26, Note 4. Loss or renegotiation of any one would materially impair earnings.
2. Disease/welfare risk. Avian Influenza and African Swine Fever remain principal risks; an independent vet review of pig farming practices concluded in Nov 2025 with recommendations now being actioned — execution/reputational risk continues 2025-11 H1 FY26.
3. Margin recovery already priced in. Adj. operating margin has rebuilt from 6.1% (H1 FY23) to 7.7% (H1 FY26); further margin gains face commodity, labour and energy inflation headwinds and the structural ceiling of meat processing economics — not disclosed but inferred.

Operating leverage

This is a moderate-to-limited operating leverage business. Cost of sales of £1,239.5m on revenue of £1,468.3m at H1 FY26 = 84.4% — i.e. raw materials, livestock and direct production costs dominate. Selling & distribution (£58.2m, 4.0%) and admin (£57.6m, 3.9%) are partially fixed but small relative to COGS. Group operating margin expanded 21bps on +10.4% revenue 2025-11 H1 FY26 — characteristic of "drop-through" of low single-digit percent on incremental revenue, not multiples of profit. Capacity-driven uplift has been visible (Hull poultry, Bury continental, Eye fresh poultry running at capacity), and management cites "excellent capacity utilisation" as a driver of margin gains, but the £600m capex programme since FY16 to add new fixed capacity means incremental volume goes through stepped fixed cost ramps, not against fully amortised plant. A 10–20% revenue surprise would likely add 30–50% to operating profit, not multiples — putting this firmly in the 30–40 range on the user's scale.

Value-trap signals

None identified. Revenue is growing high-single-digit organically, dividend has compounded (interim raised every year reported: 18.7p → 20.0p → 20.6p → 22.7p → 25.0p → 27.0p), balance sheet is conservative, no related-party concerns, no regulatory threats beyond ordinary livestock/welfare oversight, and no audit qualifications.

Earnings vs. expectations

• FY24 Q3 (Jan 2024): Trading "stronger than anticipated"; FY24 adjusted PBT "ahead of Board's previous expectations" → beat.
• H1 FY25 (Nov 2024): Adj. operating margin +67bps to 7.5%; outlook "in line with consensus" (£189.0m–£193.0m) → met/slight beat.
• H1 FY25 trading update (Sep 2024): Upgraded to "upper end of current market expectations" (£179.2m–£191.7m) → beat.
• FY26 Q1 (Jul 2025): "In line with current market expectations" (£206.5m–£213.6m) → met.
• H1 FY26 (Nov 2025): Adj. PBT +9.7%, outlook "in line with Board's expectations" → met.
• FY26 Q3 (Jan 2026): Now expected at "upper end" of £211.3m–£216.0m → beat.

Pattern: consistent in-line to modest-beat track record with management guiding conservatively and upgrading through the year — earns a 65–70 score.

Conviction

4 (high). Anchors: (1) clean, audited, well-disclosed financials with consistent APMs and reconciliations; (2) track record of delivering on capex/M&A returns supports the multiple I've used; (3) multiple methodologies (P/E, EV/EBITDA implied) converge on a similar £2.4bn–£2.8bn fair value. Limits: (1) the multiple assumed could justifiably range from 14x (de-rating risk on any weak quarter) to 20x (premium for quality), which moves fair value materially; (2) commodity input pricing and customer concentration introduce earnings variability not captured in a simple multiple.